Arcus Biosciences Stock Price To Sales
| RCUS Stock | USD 9.23 0.07 0.76% |
Fundamental analysis of Arcus Biosciences allows traders to better anticipate movements in Arcus Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Arcus Biosciences Company Price To Sales Analysis
Arcus Biosciences' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Arcus Biosciences Price To Sales | 6.88 X |
Most of Arcus Biosciences' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Arcus Biosciences has a Price To Sales of 6.8788 times. This is 67.86% lower than that of the Biotechnology sector and 93.01% lower than that of the Health Care industry. The price to sales for all United States stocks is 39.77% higher than that of the company.
Arcus Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in price to sales category among its peers.
Arcus Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.77) % | ||||
| Operating Margin | (4.36) % | ||||
| Current Valuation | 32.91 M | ||||
| Shares Outstanding | 105.89 M | ||||
| Shares Owned By Insiders | 34.93 % | ||||
| Shares Owned By Institutions | 64.99 % | ||||
| Number Of Shares Shorted | 10.05 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 6.88 X | ||||
| Revenue | 258 M | ||||
| Gross Profit | (320 M) | ||||
| EBITDA | (268 M) | ||||
| Net Income | (283 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 60 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 5.01 X | ||||
| Cash Flow From Operations | (170 M) | ||||
| Short Ratio | 10.31 X | ||||
| Earnings Per Share | (4.23) X | ||||
| Target Price | 28.18 | ||||
| Number Of Employees | 627 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 969.91 M | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 790 M | ||||
| Net Asset | 1.15 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.